Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedMar 02, 2026
DataAggregated Company Financials
Companies5
  • 7D0.1%
  • 3M-11.4%
  • 1Y-1.4%
  • YTD-9.5%

Over the last 7 days, the Biotech industry has remained flat. In line with that, the industry has also been flat over the past 12 months. Looking forward, earnings are forecast to decline by 2.0% per year.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 04 Mar 2026DKK 155.3bDKK 39.7bDKK 14.9b6.3x10.4x3.9x
Fri, 30 Jan 2026DKK 171.7bDKK 40.1bDKK 18.8b6.1x9.1x4.3x
Sun, 28 Dec 2025DKK 180.1bDKK 40.5bDKK 18.9b6.1x9.5x4.4x
Tue, 25 Nov 2025DKK 176.6bDKK 41.0bDKK 19.2b6x9.2x4.3x
Thu, 23 Oct 2025DKK 169.9bDKK 39.1bDKK 16.8b13.3x10.1x4.3x
Sat, 20 Sep 2025DKK 162.9bDKK 38.8bDKK 16.7b12.7x9.7x4.2x
Mon, 18 Aug 2025DKK 137.3bDKK 38.6bDKK 16.7b10.5x8.2x3.6x
Wed, 16 Jul 2025DKK 124.6bDKK 27.1bDKK 7.4b11x16.9x4.6x
Fri, 13 Jun 2025DKK 140.2bDKK 27.1bDKK 7.4b11.7x19x5.2x
Sun, 11 May 2025DKK 125.9bDKK 28.0bDKK 7.9b10.1x15.9x4.5x
Tue, 08 Apr 2025DKK 118.9bDKK 27.3bDKK 7.7b10.5x15.5x4.3x
Thu, 06 Mar 2025DKK 158.1bDKK 27.7bDKK 7.8b12.5x20.2x5.7x
Sat, 01 Feb 2025DKK 158.5bDKK 26.0bDKK 4.7b16.5x33.8x6.1x
Mon, 30 Dec 2024DKK 163.5bDKK 26.0bDKK 4.7b17x34.8x6.3x
Wed, 27 Nov 2024DKK 159.3bDKK 26.0bDKK 4.7b16.5x33.9x6.1x
Fri, 25 Oct 2024DKK 178.4bDKK 25.5bDKK 5.5b21.5x32.6x7x
Sun, 22 Sep 2024DKK 191.9bDKK 25.5bDKK 5.5b23.3x35.1x7.5x
Tue, 20 Aug 2024DKK 204.7bDKK 26.1bDKK 5.7b21.4x35.7x7.9x
Thu, 18 Jul 2024DKK 191.6bDKK 24.8bDKK 5.6b17.7x34x7.7x
Sat, 15 Jun 2024DKK 172.3bDKK 24.8bDKK 5.6b17.2x30.6x6.9x
Mon, 13 May 2024DKK 183.7bDKK 24.8bDKK 5.7b18.3x32.4x7.4x
Wed, 10 Apr 2024DKK 184.3bDKK 23.9bDKK 5.0b19.3x36.6x7.7x
Fri, 08 Mar 2024DKK 190.2bDKK 23.9bDKK 5.0b19.4x37.8x8x
Sun, 04 Feb 2024DKK 166.2bDKK 23.3bDKK 4.2b22.8x39.9x7.1x
Tue, 02 Jan 2024DKK 177.2bDKK 23.3bDKK 4.2b25.9x42.6x7.6x
Thu, 30 Nov 2023DKK 172.8bDKK 23.3bDKK 4.2b25.2x41.5x7.4x
Sat, 28 Oct 2023DKK 158.4bDKK 22.0bDKK 4.7b18.5x33.4x7.2x
Mon, 25 Sep 2023DKK 196.1bDKK 22.0bDKK 4.7b23x41.4x8.9x
Wed, 23 Aug 2023DKK 194.1bDKK 20.6bDKK 3.9b36.7x49.2x9.4x
Fri, 21 Jul 2023DKK 210.0bDKK 19.5bDKK 4.4b41.5x47.7x10.7x
Sun, 18 Jun 2023DKK 208.1bDKK 19.5bDKK 4.4b44x47.2x10.6x
Tue, 16 May 2023DKK 220.1bDKK 17.9bDKK 4.0b34x55.1x12.3x
Thu, 13 Apr 2023DKK 201.4bDKK 17.9bDKK 3.5b31.4x56.9x11.2x
Sat, 11 Mar 2023DKK 189.1bDKK 17.9bDKK 3.5b29.2x53.3x10.6x
Price to Earnings Ratio

53.3x


Total Market Cap: DKK 189.1bTotal Earnings: DKK 3.5bTotal Revenue: DKK 17.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 30.7x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 10.4x which is lower than its 3-year average PE of 30.8x.
  • The 3-year average PS ratio of 6.9x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 61% per year over the last three years.
  • Revenues for these companies have grown 30% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-7.16%
Healthcare-15.42%
Biotech0.11%
Biotech0.11%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
No data available

Latest News

GMAB
DKK 1,766.00
Genmab
7D
-4.6%
1Y
7.6%

GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook

Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.
BAVA
DKK 185.00
Bavarian Nordic
7D
-6.0%
1Y
13.1%
ZEAL
DKK 356.50
Zealand Pharma
7D
-2.4%
1Y
-37.1%

ZEAL: Positive Immunology Data And Metabolic Partnership Will Support Future Upside

Analysts have trimmed their price target on Zealand Pharma by DKK 5 to reflect updated assumptions for revenue growth, profit margins and a higher forward P/E. They have kept the overall discount rate broadly in line with prior views.
BIOPOR
DKK 0.89
BioPorto
7D
-7.2%
1Y
-39.1%
STRAP
DKK 580.00
Strategic Partners
7D
-7.1%
1Y
-29.7%